ImCheck Therapeutics vs ImmunoScape
ImCheck Therapeutics vs ImmunoScape, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: ImCheck Therapeutics is on 60/100 and ImmunoScape on 58/100.
Where each one leads
ImCheck Therapeutics
- domain rating: 37/100 against 28/100
- funding raised: $164M against $49.7M
- LinkedIn following: 11,647 against 4,364
ImmunoScape
- agent readiness: 39/100 against 34/100
At a glance
| Measure | ImCheck Therapeutics | ImmunoScape |
|---|---|---|
| What it is | ImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies. | Developing novel immunotherapies and diagnostics for cancer. |
| Category | Biotech, MedTech, HealthTech, Drug Discovery | Biotechnology, Cancer, Immunotherapy, Diagnostics |
| Sells toBusiness model | B2B | B2B |
| Offering | Biotech | Platform |
| Founded | 2015 | 2017 |
| Headquarters | Marseille, France | Singapore, Singapore |
| Status | Active | Active |
Size, funding and growth
| Measure | ImCheck Therapeutics | ImmunoScape |
|---|---|---|
| Employees | 47 | Not published |
| Total funding | $164M | $49.7M |
| Latest round | Not published | Series B2 |
| Valuation | Not published | $1.1B |
| LinkedIn followers | 11,647 | 4,364 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | ImCheck Therapeutics | ImmunoScape |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 60/100 | 58/100 |
| Traction | 57/100 | 38/100 |
| Team | 70/100 | 70/100 |
| Community | 15/100 | Not published |
| Search visibility | 22/100 | 23/100 |
| Quality | 68/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (34/100) | F (39/100) |
| Domain ratingLink authority, 0-100 | 37/100 | 28/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | ImCheck Therapeutics | ImmunoScape |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Jquery, Tailwind CSS, Bootstrap | Jquery |
| Analytics | Google Analytics 4 | Google Tag Manager |
What users say
| Measure | ImCheck Therapeutics | ImmunoScape |
|---|---|---|
| Reddit sentimentThreads we track | Not published | 6 positive, 0 negative across 6 threads |
“Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments.”r/Quantisnow
ImCheck Therapeutics vs ImmunoScape: common questions
Which is better, ImCheck Therapeutics or ImmunoScape?
On our 0-100 score ImCheck Therapeutics rates higher (60/100 against 58/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do ImCheck Therapeutics and ImmunoScape compare on the numbers?
ImCheck Therapeutics leads on domain rating (37/100 against 28/100), funding raised ($164M against $49.7M), LinkedIn following (11,647 against 4,364). ImmunoScape leads on agent readiness (39/100 against 34/100).
What do real users say about ImCheck Therapeutics and ImmunoScape?
ImmunoScape: 6 positive and 0 negative mentions across 6 Reddit threads we track, mostly in r/Quantisnow.
Read the full ImCheck Therapeutics review and pricing or the ImmunoScape review and pricing. You can also browse other ImCheck Therapeutics alternatives we track.